Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX-2982 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX-2982 25 mg | EXPERIMENTAL | - |
| MBX-2982 100 mg | EXPERIMENTAL | - |
| MBX-2982 300 mg | EXPERIMENTAL | - |
| Sitagliptin 100 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MBX-2982 | DRUG | tablets and capsule once daily |
| Sitagliptin | DRUG | tablets and capsule once daily |
| placebo | DRUG | tablets and capsule once daily |
Inclusion Criteria: * History of type 2 diabetes of at least 3 months duration * Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone) * HbA1c 7.0-8.5% (inclusive) at sc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
MBX-2982 is an investigational small molecule being developed for the treatment of diabetes. It was studied as a monotherapy in patients with type 2 diabetes. The drug is in Phase 2 clinical development and is not approved by the FDA.
MBX-2982 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 2 clinical development for the treatment of diabetes.
MBX-2982 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities.
MBX-2982 has one completed clinical trial, NCT01035879, which evaluated the efficacy, safety, tolerability, and pharmacokinetics of the drug administered daily for 4 weeks as monotherapy in patients with type 2 diabetes. The trial enrolled 100 participants in the United States, Georgia, and India.
MBX-2982 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of diabetes. The completed Phase 2 trial was a randomized, double-blind, placebo-controlled study, but the drug has not yet received regulatory approval.